Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)’s proposed $10 million equity agreement with AOP Health International Management “should provide some much-needed breathing room” for the AIM-listed pharma group, said Stifel analysts.
“This, along with the business looking to lower its cost base by circa 10%, will help strengthen the balance sheet and support achieving cash flow breakeven by 2025 year-end,” they stated, adding that the company is “on track for 2024”.
Stifel’s comments follow a Thursday trading update from Shield, which showed that the company is on track to meet its full-year 2024 revenue target of $31.5 million.
According to Stifel, strong sales growth for iron deficiency drug ACCRUFeR will be the key ingredient to Shield hitting mid-term targets.
So far so good- Shield reported strong sales of ACCRUFeR in October, bolstered by an increase in the net selling price to over $225 per prescription, up from $167 in the third quarter of 2024.
Stifel has a 3.5p per share price target on Shield shares against a Thursday price of 2.88p.